Nucleic acids for nuclease-mediated genome editing

Patent metadata

Field	Value
Publication number	US-12534715-B2
Application number	US-202318461941-A
Country	US
Kind code	B2
Filing date	Sep 6, 2023
Priority date	Apr 16, 2015
Publication date	Jan 27, 2026
Grant date	Jan 27, 2026

Abstract

The invention related to the field of genetic engineering tools, methods and techniques for gene or genome editing. Specifically, the invention concerns isolated polypeptides having nuclease activity, host cells and expression vectors comprising nucleic acids encoding said polypeptides as well as methods of cleaving and editing target nucleic acids in a sequence-specific matter. The poly peptides, nucleic acids, expression vectors, host cells and methods of the present invention have application in many fields of biotechnology, including, for example, synthetic biology and gene therapy.

First claim

The invention claimed is:

1 . A composition comprising:
(a) an mRNA encoding a Cpf1 polypeptide comprising SEQ ID NO: 1 or an amino acid sequence having at least 95% identity to the polypeptide of SEQ ID NO: 1, wherein the Cpf1 polypeptide comprises a RuvC-like domain, does not comprise an HNH domain, and has nuclease activity, and (b) an engineered guide RNA comprising a sequence substantially complementary to a target nucleic acid sequence.

2 . The composition of claim 1 , wherein the Cpf1 polypeptide has at least 98% identity to the polypeptide of SEQ ID NO: 1.

3 . The composition of claim 1 , wherein the Cpf1 polypeptide comprises an arginine-rich motif.

4 . The composition of claim 1 , wherein the Cpf1 polypeptide comprises a zinc finger-domain having a metal-binding site.

5 . The composition of claim 1 , wherein an additional protein domain is fused to the N- or C-terminus of the Cpf1 polypeptide.

6 . The composition of claim 5 , wherein the additional protein domain has nucleic acid or chromatin modifying, transcription activating, or transcription repressing activity.

7 . The composition of claim 5 , wherein the additional protein domain comprises a nuclear localization signal.

8 . The composition of claim 1 , wherein the Cpf1 polypeptide comprises an amino acid sequence motif comprising residues 783-794, 784-794, 785-794, 786-794, 787-794, 788-794, 789-794, 783-793, 783-792, 783-791, 783-790, 783-789, 783-788, 784-793, 785-792, or 786-790 of SEQ ID NO: 1.

9 . The composition of claim 1 , wherein the Cpf1 polypeptide comprises at least one mutation compared to the polypeptide of SEQ ID NO:1.

10 . The composition of claim 1 , wherein the composition is configured for intracellular delivery.

11 . The composition of claim 1 , wherein the Cpf1 polypeptide has at least 99% identity to the polypeptide of SEQ ID NO: 1.

Assignees

• Univ Wageningen

Inventors

• Van Der Oost John

Classifications

• C12N2310/20

  involving clustered regularly interspaced short palindromic repeats [CRISPR] · CPC title

• C07K2319/09

  containing a nuclear localisation signal · CPC title

• C12N15/11

  DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity} · CPC title

• C12N9/22 Primary

  Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title

• C12N9/222 Primary

  Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes · CPC title